Why Does the Injection Site Matter
Bellamy MF, McDowell IFW, Ramsey MW, Brownlee M, Bones C, Newcombe RG, and Lewis MJ (1998)
Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5-monophosphate (AMP)-activated protein kinase signaling pathway
The model included age group, gender, BMI, smoking cessation aid use, and duration of GLP-1 use as covariates, and results were reported as adjusted odds ratios (aORs) with 95% confidence intervals (CIs)
What This Means for You These patterns provide general guidance but dont determine individual outcomes
This counterintuitive outcome can happen for several clinical reasons, ranging from medication interruptions to individual variations in how your body responds to GLP-1 therapy